Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.

@article{Hu2011ValproateRT,
  title={Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways.},
  author={Jiang-Ping Hu and Jing-Wei Xie and Chun-yan Wang and Tao Wang and Xu Wang and Siling Wang and Weiping Teng and Zhan-You Wang},
  journal={Brain research bulletin},
  year={2011},
  volume={85 3-4},
  pages={194-200}
}
Valproate (VPA) is a widely used anticonvulsant and mood-stabilizing drug. Recent studies have shown that VPA could reduce amyloid-β generation, and improve memory deficits in transgenic mouse models of Alzheimer's disease (AD). However, whether VPA affects tau phosphorylation and the underlying mechanism has not been established. Here, we showed that systemic treatment of APP and presenilin 1 double transgenic mice with VPA (50mg/kg, once a day for 12 weeks), significantly reduced the levels… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo

  • L. Sereno, M. Coma, +10 authors T. Gomez- Isla
  • Neurobiol. Dis. 35 (2009) 359–367. 200 J.-P. Hu…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…